The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
287
oral tablets, once daily for 8 weeks
capsules, once daily for 8 weeks
Unnamed facility
Beijing, China
Unnamed facility
Chongqing, China
Unnamed facility
Guangzhou, China
Unnamed facility
Nanjing, China
Unnamed facility
Shanghai, China
Change of trough seated diastolic blood pressure from baseline to 8 weeks
Time frame: Baseline to 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.